Nifelat (Nifedipine)

Nifedipine, the active ingredient in Nifelat, is a calcium channel blocker presented as an oral tablet for systemic use. It is employed to manage high blood pressure, relieve chest pain from angina, and improve blood flow in Raynaud's phenomenon, primarily in adult patients.

GNH USA supplies Nifelat as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established quality‑assurance processes and regulatory approvals across multiple jurisdictions. Our distribution network ensures reliable delivery and compliance with local import requirements.

Nifelat (nifedipine) acts on the cardiovascular system by relaxing vascular smooth muscle, making it useful for several related conditions.

- Hypertension: reduces systemic vascular resistance, leading to lower arterial pressure and improved blood pressure control. - Angina pectoris: dilates coronary arteries and decreases cardiac workload, helping to prevent chest pain episodes. - Raynaud's phenomenon: improves peripheral blood flow by relaxing arterioles, reducing the frequency and severity of vasospastic attacks.

Nifedipine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Flushing: warm sensation and redness of the skin. - Headache: often mild to moderate intensity. - Peripheral edema: swelling of ankles or feet. - Dizziness or light‑headedness. - Tachycardia: increased heart rate. - Nausea or abdominal discomfort.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure. - Myocardial infarction: rare but possible cardiac event. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Allergic reactions: rash, itching, or anaphylaxis. - Atrioventricular block: conduction disturbances. - Pulmonary edema: fluid accumulation in lungs.

When prescribing Nifelat, clinicians should consider several safety measures to minimize risks. - Blood pressure monitoring: check baseline and periodic readings. - Gradual dose titration: avoid abrupt dose changes to reduce hypotension risk. - Hepatic impairment: use caution and consider dose adjustment. - Concomitant antihypertensives: monitor for additive blood‑pressure‑lowering effects. - Pregnancy and lactation: evaluate risk‑benefit and consult obstetric guidance. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture and light.

Nifelat can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may cause dangerous hypotension. - Concurrent use with other potent vasodilators (e.g., nitroglycerin): risk of excessive blood pressure drop.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce nifedipine plasma levels. - Grapefruit juice: can increase drug concentration, enhancing side effects. - Beta‑blockers: may mask tachycardia, requiring heart rate monitoring. - Diuretics: additive effect on blood pressure, monitor electrolytes. - Antacids containing aluminum or magnesium: may affect absorption, separate dosing by at least 2 hours.